Intra-Cellular Therapies (ITCI) Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings or view top-rated stocks.

8 brokers have issued 1 year price objectives for Intra-Cellular Therapies' shares. Their ITCI share price forecasts range from $62.00 to $98.00. On average, they predict the company's share price to reach $78.78 in the next twelve months. This suggests a possible upside of 51.2% from the stock's current price.
View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts.

Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of 2023. Since then, ITCI shares have decreased by 1.6% and is now trading at $52.09.
View the best growth stocks for 2023 here.

Intra-Cellular Therapies saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 2,230,000 shares, a decrease of 12.5% from the August 31st total of 2,550,000 shares. Based on an average daily trading volume, of 639,800 shares, the short-interest ratio is presently 3.5 days.
View Intra-Cellular Therapies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ITCI earnings forecast.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.17. The biopharmaceutical company earned $110.80 million during the quarter, compared to the consensus estimate of $106.45 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 28.63% and a negative net margin of 50.40%. Intra-Cellular Therapies's revenue for the quarter was up 99.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.92) EPS.

ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ITCI stock can currently be purchased for approximately $52.09.

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.00 billion and generates $250.31 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

The company employs 561 workers across the globe.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.